News articles about Roka Bioscience (NASDAQ:ROKA) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Roka Bioscience earned a media sentiment score of 0.02 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 45.0406015757399 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Shares of Roka Bioscience (ROKA) traded up $0.07 on Friday, hitting $1.12. The stock had a trading volume of 209,374 shares, compared to its average volume of 441,596. Roka Bioscience has a fifty-two week low of $0.66 and a fifty-two week high of $6.20.

In other news, major shareholder Orbimed Advisors Llc sold 201,617 shares of the stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $0.68, for a total value of $137,099.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders sold 803,894 shares of company stock valued at $603,915. 29.20% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/11/26/roka-bioscience-roka-earning-somewhat-favorable-news-coverage-study-finds.html.

About Roka Bioscience

Roka Bioscience, Inc is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications.

Insider Buying and Selling by Quarter for Roka Bioscience (NASDAQ:ROKA)

Receive News & Stock Ratings for Roka Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roka Bioscience Inc. and related stocks with our FREE daily email newsletter.